Storia in 3 fonti

Amgen stands by Tavneos, despite reports of 20 deaths in Japan

The FDA wants Amgen's Tavneos off the market. European regulators are investigating data-integrity concerns. And now, a pharma selling the drug in Japan is warning doctors against writing more prescriptions.

Raccontata da

endpoints.news

swissinfo.ch

fiercepharma.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mesi fa

Amgen stands by Tavneos, despite reports of 20 deaths in Japan

originale

fiercepharma.com1 mesi fa

Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med Tavneos (avacopan), alb | After the drug’s…

Leggi questa versione →

Timeline cronologica

lunedì 18 maggio 2026·endpoints.news
Amgen stands by Tavneos, despite reports of 20 deaths in Japan
The FDA wants Amgen's Tavneos off the market. European regulators are investigating data-integrity concerns. And now, a pharma selling the drug in Japan is warning doctors against…
martedì 19 maggio 2026·swissinfo.ch
Switzerland monitors Japanese concerns over Tavneos drug
Swissmedic closely monitoring international developments around the drug Tavneos.

Amgen stands by Tavneos, despite reports of 20 deaths in Japan

Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume

Timeline cronologica

Amgen stands by Tavneos, despite reports of 20 deaths in Japan

Switzerland monitors Japanese concerns over Tavneos drug

Switzerland monitors Japanese concerns over Tavneos drug

Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume